New Delhi, June 24 -- Danish drugmaker Novo Nordisk is betting on its insulin leadership in India to dominate the country's $25-billion anti-obesity drug market with the imminent launch of its weight-loss therapy, a top company official said.

Novo Nordisk is preparing to launch Wegovy in India, where millions of people are battling obesity and demand for the weight-loss drug is expected to be massive. The drug will be launched in several dosage strengths at accessible price-points.

"We are launching with full preparation and we are launching with a big bang to make it happen in India," Vikrant Shrotriya, managing director of Novo Nordisk India, told Mint in an interview.

Also read: Ozempic, a patent challenge, and $25 bn race for India...